Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy: A randomised controlled trial

Fung W. Chang, Mu Hsien Yu, Chih Hung Ku, Chi Huang Chen, Gwo Jang Wu, Jah Y. Liu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To investigate the effectiveness of uterotonics misoprostol and oxytocin on reducing blood loss during laparoscopy-assisted vaginal hysterectomy (LAVH). Design: Randomised, double-blind placebo-controlled trial. Setting: University hospital. Population: One hundred and seventy-three women underwent LAVH for symptomatic uterine myomas and were randomly allocated to uterotonics (n= 91) or placebo (n= 82). Methods: Women underwent LAVH for symptomatic uterine myomas and were randomly assigned to receive either rectal misoprostol (400 μg) and intravenous oxytocin (10 IU/hour) or placebo during LAVH. Parameters related to surgical outcome were compared. Main outcome measures: The main outcome measure was intra-operative blood loss. Results: Patient characteristics and indications for LAVH were similar in both groups. Mean [SD] for all continuous data estimated weight of blood loss (198.1 [123.2] vs 396 [337.6] g; P <0.0001), mean operation time (106.2 [39.4] vs 116.6 [34.6] minutes; P= 0.02), mean change in haemoglobin (1.5 [1.0] vs 1.9 [1.2] g/dL; P= 0.02) and haematocrit levels (4.8 [2.9]% vs 5.8 [3.6]%; P= 0.04) and mean hospitalisation period (3.3 [0.8] vs 3.9 [1.1] days; P <0.0001), which were significantly less in the group given rectal misoprostol and intravenous oxytocin than in the placebo group, respectively. There was no significant difference in complications and side effects between the two groups (P > 0.05). Conclusion: Combined rectal misoprostol and intravenous oxytocin is a feasible and effective method of reducing blood loss and operation time in LAVH.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalBJOG: An International Journal of Obstetrics and Gynaecology
Volume113
Issue number1
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Fingerprint

Vaginal Hysterectomy
Laparoscopy
Randomized Controlled Trials
Misoprostol
Oxytocin
Myoma
Placebos
Outcome Assessment (Health Care)
Weight Loss
Population

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy : A randomised controlled trial. / Chang, Fung W.; Yu, Mu Hsien; Ku, Chih Hung; Chen, Chi Huang; Wu, Gwo Jang; Liu, Jah Y.

In: BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 113, No. 1, 01.2006, p. 47-52.

Research output: Contribution to journalArticle

@article{08fa180f4f704c7b857bbbb8f30f86c1,
title = "Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy: A randomised controlled trial",
abstract = "Objective: To investigate the effectiveness of uterotonics misoprostol and oxytocin on reducing blood loss during laparoscopy-assisted vaginal hysterectomy (LAVH). Design: Randomised, double-blind placebo-controlled trial. Setting: University hospital. Population: One hundred and seventy-three women underwent LAVH for symptomatic uterine myomas and were randomly allocated to uterotonics (n= 91) or placebo (n= 82). Methods: Women underwent LAVH for symptomatic uterine myomas and were randomly assigned to receive either rectal misoprostol (400 μg) and intravenous oxytocin (10 IU/hour) or placebo during LAVH. Parameters related to surgical outcome were compared. Main outcome measures: The main outcome measure was intra-operative blood loss. Results: Patient characteristics and indications for LAVH were similar in both groups. Mean [SD] for all continuous data estimated weight of blood loss (198.1 [123.2] vs 396 [337.6] g; P <0.0001), mean operation time (106.2 [39.4] vs 116.6 [34.6] minutes; P= 0.02), mean change in haemoglobin (1.5 [1.0] vs 1.9 [1.2] g/dL; P= 0.02) and haematocrit levels (4.8 [2.9]{\%} vs 5.8 [3.6]{\%}; P= 0.04) and mean hospitalisation period (3.3 [0.8] vs 3.9 [1.1] days; P <0.0001), which were significantly less in the group given rectal misoprostol and intravenous oxytocin than in the placebo group, respectively. There was no significant difference in complications and side effects between the two groups (P > 0.05). Conclusion: Combined rectal misoprostol and intravenous oxytocin is a feasible and effective method of reducing blood loss and operation time in LAVH.",
author = "Chang, {Fung W.} and Yu, {Mu Hsien} and Ku, {Chih Hung} and Chen, {Chi Huang} and Wu, {Gwo Jang} and Liu, {Jah Y.}",
year = "2006",
month = "1",
doi = "10.1111/j.1471-0528.2005.00804.x",
language = "English",
volume = "113",
pages = "47--52",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy

T2 - A randomised controlled trial

AU - Chang, Fung W.

AU - Yu, Mu Hsien

AU - Ku, Chih Hung

AU - Chen, Chi Huang

AU - Wu, Gwo Jang

AU - Liu, Jah Y.

PY - 2006/1

Y1 - 2006/1

N2 - Objective: To investigate the effectiveness of uterotonics misoprostol and oxytocin on reducing blood loss during laparoscopy-assisted vaginal hysterectomy (LAVH). Design: Randomised, double-blind placebo-controlled trial. Setting: University hospital. Population: One hundred and seventy-three women underwent LAVH for symptomatic uterine myomas and were randomly allocated to uterotonics (n= 91) or placebo (n= 82). Methods: Women underwent LAVH for symptomatic uterine myomas and were randomly assigned to receive either rectal misoprostol (400 μg) and intravenous oxytocin (10 IU/hour) or placebo during LAVH. Parameters related to surgical outcome were compared. Main outcome measures: The main outcome measure was intra-operative blood loss. Results: Patient characteristics and indications for LAVH were similar in both groups. Mean [SD] for all continuous data estimated weight of blood loss (198.1 [123.2] vs 396 [337.6] g; P <0.0001), mean operation time (106.2 [39.4] vs 116.6 [34.6] minutes; P= 0.02), mean change in haemoglobin (1.5 [1.0] vs 1.9 [1.2] g/dL; P= 0.02) and haematocrit levels (4.8 [2.9]% vs 5.8 [3.6]%; P= 0.04) and mean hospitalisation period (3.3 [0.8] vs 3.9 [1.1] days; P <0.0001), which were significantly less in the group given rectal misoprostol and intravenous oxytocin than in the placebo group, respectively. There was no significant difference in complications and side effects between the two groups (P > 0.05). Conclusion: Combined rectal misoprostol and intravenous oxytocin is a feasible and effective method of reducing blood loss and operation time in LAVH.

AB - Objective: To investigate the effectiveness of uterotonics misoprostol and oxytocin on reducing blood loss during laparoscopy-assisted vaginal hysterectomy (LAVH). Design: Randomised, double-blind placebo-controlled trial. Setting: University hospital. Population: One hundred and seventy-three women underwent LAVH for symptomatic uterine myomas and were randomly allocated to uterotonics (n= 91) or placebo (n= 82). Methods: Women underwent LAVH for symptomatic uterine myomas and were randomly assigned to receive either rectal misoprostol (400 μg) and intravenous oxytocin (10 IU/hour) or placebo during LAVH. Parameters related to surgical outcome were compared. Main outcome measures: The main outcome measure was intra-operative blood loss. Results: Patient characteristics and indications for LAVH were similar in both groups. Mean [SD] for all continuous data estimated weight of blood loss (198.1 [123.2] vs 396 [337.6] g; P <0.0001), mean operation time (106.2 [39.4] vs 116.6 [34.6] minutes; P= 0.02), mean change in haemoglobin (1.5 [1.0] vs 1.9 [1.2] g/dL; P= 0.02) and haematocrit levels (4.8 [2.9]% vs 5.8 [3.6]%; P= 0.04) and mean hospitalisation period (3.3 [0.8] vs 3.9 [1.1] days; P <0.0001), which were significantly less in the group given rectal misoprostol and intravenous oxytocin than in the placebo group, respectively. There was no significant difference in complications and side effects between the two groups (P > 0.05). Conclusion: Combined rectal misoprostol and intravenous oxytocin is a feasible and effective method of reducing blood loss and operation time in LAVH.

UR - http://www.scopus.com/inward/record.url?scp=33644807995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644807995&partnerID=8YFLogxK

U2 - 10.1111/j.1471-0528.2005.00804.x

DO - 10.1111/j.1471-0528.2005.00804.x

M3 - Article

C2 - 16398771

AN - SCOPUS:33644807995

VL - 113

SP - 47

EP - 52

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 1

ER -